Johnson & Johnson (JNJ) Stock Moves -0.99%: What You Should Know
Zacks Investment Research | Oct 08, 2019 05:45AM ET
In the latest trading session, Johnson & Johnson (NYSE:JNJ) closed at $131.84, marking a -0.99% move from the previous day. This change was narrower than the S&P 500's 1.56% loss on the day. At the same time, the Dow lost 1.19%, and the tech-heavy Nasdaq lost 1.67%.
Coming into today, shares of the world's biggest maker of health care products had gained 4.89% in the past month. In that same time, the Medical sector lost 3.6%, while the S&P 500 lost 1.22%.
Wall Street will be looking for positivity from JNJ as it approaches its next earnings report date. This is expected to be October 15, 2019. In that report, analysts expect JNJ to post earnings of $2 per share. This would mark a year-over-year decline of 2.44%. Meanwhile, our latest consensus estimate is calling for revenue of $20.05 billion, down 1.45% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $8.60 per share and revenue of $81.51 billion, which would represent changes of +5.13% and -0.09%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for JNJ. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. JNJ currently has a Zacks Rank of #4 (Sell).
Digging into valuation, JNJ currently has a Forward P/E ratio of 15.49. For comparison, its industry has an average Forward P/E of 14.44, which means JNJ is trading at a premium to the group.
We can also see that JNJ currently has a PEG ratio of 2.25. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.11 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 35, putting it in the top 14% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Get The News You Want
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.